Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 74.30

+0.2%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	6/7/2011 11:06:23 AM
	of 4676

Isis Pharmaceuticals announces publication of new data concerning microRNA-33 Regulus Therapeutics, part of Isis Pharmaceuticals, announced publication in the Journal of Clinical Investigation of new pre-clinical data in mice on the antagonism of microRNA-33. The study, performed with collaborators at NYU Langone Medical Center, demonstrated that antagonism of miR-33 with proprietary chemically modified anti-miR oligonucleotides can promote clearance of excess cholesterol and statistically significant regression of atherosclerosis in mice with established atherosclerotic plaques.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next